CKD-mineral and bone disorder: core curriculum 2011.
作者信息
Moorthi Ranjani N, Moe Sharon M
机构信息
Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN 46202, USA.
出版信息
Am J Kidney Dis. 2011 Dec;58(6):1022-36. doi: 10.1053/j.ajkd.2011.08.009. Epub 2011 Oct 21.
Abstract
摘要
相似文献
1
CKD-mineral and bone disorder: core curriculum 2011.慢性肾脏病-矿物质和骨异常：2011年核心课程
Am J Kidney Dis. 2011 Dec;58(6):1022-36. doi: 10.1053/j.ajkd.2011.08.009. Epub 2011 Oct 21.
2
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常（CKD-MBD）的磷结合剂。
Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3.
3
Effectiveness and cost-efficacy of phosphate binders in hemodialysis.血液透析中磷结合剂的有效性和成本效益。
Ann Nutr Metab. 2011 Oct;58(4):315-9. doi: 10.1159/000331988. Epub 2011 Oct 7.
4
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.慢性肾脏病中的甲状旁腺功能：成纤维细胞生长因子23-klotho轴的作用
Contrib Nephrol. 2013;180:110-23. doi: 10.1159/000346791. Epub 2013 May 3.
5
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].[透析开始前慢性肾脏病中磷的控制及维生素D治疗]
Nefrologia. 2008;28 Suppl 5:39-45.
6
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.慢性肾脏病中磷结合剂的益处与危害：随机对照试验的系统评价
Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18.
7
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?慢性肾脏病：磷结合剂治疗——坚固堡垒出现裂痕？
Nat Rev Nephrol. 2012 Nov;8(11):615-6. doi: 10.1038/nrneph.2012.219. Epub 2012 Oct 9.
8
Effects of phosphate binders in moderate CKD.中重度 CKD 患者的磷酸盐结合剂治疗效果。
J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19.
9
Managing bone mineral disorders in CKD: an overview of current therapies.慢性肾脏病中骨矿物质紊乱的管理：当前治疗方法概述
J Ren Care. 2009 Mar;35 Suppl 1:107-10. doi: 10.1111/j.1755-6686.2009.00061.x.
10
Update on the treatment of chronic kidney disease-mineral and bone disorder.慢性肾脏病-矿物质和骨异常的治疗进展
J Ren Care. 2009 Mar;35 Suppl 1:19-27. doi: 10.1111/j.1755-6686.2009.00049.x.
引用本文的文献
1
The Calcimimetic R568 Reduces Vascular Smooth Muscle Cell Calcification in Vitro Via ERK 1/2 Phosphorylation.拟钙剂R568通过细胞外信号调节激酶1/2磷酸化减少体外血管平滑肌细胞钙化。
Int J Nephrol. 2025 Mar 18;2025:2492846. doi: 10.1155/ijne/2492846. eCollection 2025.
2
Evaluation of MicroRNA 145 and MicroRNA 155 as Markers of Cardiovascular Risk in Chronic Kidney Disease.评估微小RNA 145和微小RNA 155作为慢性肾脏病心血管风险标志物的作用
Cureus. 2024 Aug 9;16(8):e66494. doi: 10.7759/cureus.66494. eCollection 2024 Aug.
3
The Effects of Acid on Calcium and Phosphate Metabolism.酸对钙磷代谢的影响。
Int J Mol Sci. 2024 Feb 8;25(4):2081. doi: 10.3390/ijms25042081.
4
The refractory secondary hyperparathyroidism presenting with retro-orbital brown tumor: a case report.难治性甲状旁腺功能亢进症伴眼眶后棕色瘤：病例报告。
BMC Nephrol. 2024 Jan 5;25(1):15. doi: 10.1186/s12882-024-03455-8.
5
Nanocrystal-induced chronic tubular-nephropathy in tropical countries: diagnosis, mitigation, and eradication.纳米晶体诱导的热带国家慢性肾小管肾病：诊断、缓解和消除。
Eur J Med Res. 2023 Jul 5;28(1):221. doi: 10.1186/s40001-023-01162-y.
6
Coronary artery calcification in patients with advanced chronic kidney disease.晚期慢性肾脏病患者的冠状动脉钙化。
BMC Cardiovasc Disord. 2022 Oct 29;22(1):453. doi: 10.1186/s12872-022-02879-0.
7
Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.肾脏病患者的矿物质和骨代谢紊乱：永恒的话题。
Int J Mol Sci. 2022 Oct 13;23(20):12223. doi: 10.3390/ijms232012223.
8
Effect of Dietary Phosphorous Restriction on Fibroblast Growth 2 Factor-23 and sKlotho Levels in Patients with Stages 1-2 Chronic Kidney Disease.饮食磷限制对 1-2 期慢性肾脏病患者成纤维细胞生长因子 23 和 Klotho 水平的影响。
Nutrients. 2022 Aug 12;14(16):3302. doi: 10.3390/nu14163302.
9
First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants.在健康的日本成年参与者中进行新型可注射钙敏感受体激动剂 Upacicalcet 的首次人体 I 期研究。
Drugs R D. 2022 Jun;22(2):131-140. doi: 10.1007/s40268-022-00385-4. Epub 2022 Mar 25.
10
Uremic Leontiasis Ossea in a Patient With End-Stage Renal Disease in Hemodialysis.一名接受血液透析的终末期肾病患者的尿毒症性骨性狮面症
Cureus. 2020 Oct 20;12(10):e11060. doi: 10.7759/cureus.11060.
本文引用的文献
1
Efficacy of sodium thiosulfate for the treatment for calciphylaxis.硫代硫酸钠治疗钙过敏的疗效。
Clin Nephrol. 2011 Jun;75(6):485-90. doi: 10.5414/cnp75485.
2
Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.新千年第一个十年的肾性骨营养不良：对黑人和白人患者 630 例骨活检的分析。
J Bone Miner Res. 2011 Jun;26(6):1368-76. doi: 10.1002/jbmr.309.
3
Signalling pathways and vascular calcification.信号通路与血管钙化。
Front Biosci (Landmark Ed). 2011 Jan 1;16(4):1302-14. doi: 10.2741/3790.
4
Sodium thiosulfate-based treatment in calcific uremic arteriolopathy: a consecutive case series.硫代硫酸钠治疗钙化性尿毒症小动脉病：连续病例系列
Clin Nephrol. 2011 Jan;75(1):8-15.
5
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.ADVANCE 研究：一项随机研究，评估西那卡塞联合小剂量维生素 D 对血液透析患者血管钙化的影响。
Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. doi: 10.1093/ndt/gfq725. Epub 2010 Dec 8.
6
In-center hemodialysis six times per week versus three times per week.每周中心血液透析 6 次与每周 3 次的比较。
N Engl J Med. 2010 Dec 9;363(24):2287-300. doi: 10.1056/NEJMoa1001593. Epub 2010 Nov 20.
7
Confusion on the complexity of calcium balance.对钙平衡复杂性的困惑。
Semin Dial. 2010 Sep-Oct;23(5):492-7. doi: 10.1111/j.1525-139x.2010.00771.x.
8
Renal bone disease.肾脏骨病。
Curr Opin Endocrinol Diabetes Obes. 2010 Dec;17(6):535-9. doi: 10.1097/MED.0b013e3283400945.
9
Atherosclerosis in CKD: differences from the general population.慢性肾脏病患者的动脉粥样硬化：与普通人群的差异。
Nat Rev Nephrol. 2010 Dec;6(12):723-35. doi: 10.1038/nrneph.2010.143. Epub 2010 Oct 26.
10
Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials.维生素 D 补充治疗慢性肾脏病：系统评价和观察性研究及随机对照试验的荟萃分析。
Clin J Am Soc Nephrol. 2011 Jan;6(1):50-62. doi: 10.2215/CJN.03940510. Epub 2010 Sep 28.
Zotero 插件